Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
This study is exploring new treatment combinations for people with advanced cancers such as lung cancer, head and neck cancer, and melanoma. Researchers are looking at a new drug called EOS-448 (also known as belrestotug) and combining it with other existing cancer drugs like pembrolizumab or dostarlimab, or with another new drug called inupadenant. They are also testing some of these combinations alongside standard chemotherapy. The main goals are to check if these new combinations are safe, how well they are tolerated, and if they can help shrink tumours. This research could lead to new ways to treat these advanced cancers.
At a glance
What is this study about?
This study is a clinical trial looking for better ways to treat advanced cancers when standard treatments might not be enough or have stopped working. The researchers are particularly interested in a new drug called EOS-448, also known by other names like belrestotug. EOS-448 is being tested in several different ways, sometimes on its own with other drugs, and sometimes alongside standard chemotherapy treatments.
The main idea behind this study is to see if combining different cancer drugs can be more effective than using them alone. For example, they are testing EOS-448 with drugs like pembrolizumab and dostarlimab, which are types of immunotherapy that help your own immune system fight cancer. They're also trying EOS-448 with another new drug called inupadenant. For some people with lung cancer, these combinations might be given with standard chemotherapy.
By carefully studying these combinations, the research team hopes to understand how safe they are, what side effects they might cause, and importantly, if they can help slow down or shrink the cancer. The information gathered from this study will help doctors decide if these new treatments could benefit people with these types of advanced cancers in the future.
Key takeaways
- Tests new drug EOS-448 in combinations for advanced cancers.
- Aims to find safe and effective new treatments.
- Includes lung, head & neck cancer, and melanoma.
- Involves immunotherapies and standard chemotherapy.
- Only for adults aged 18 and over.
- Participation is voluntary and can be stopped at any time.
Who may be eligible?
This study is for adults aged 18 or older with advanced solid tumours, which means cancers like lung cancer, head and neck cancer, and melanoma that have spread. You would need to have cancer that can be measured by scans and generally be well enough to take part, meaning you can mostly look after yourself and do light activities. Your body's organs, like your heart, liver, and kidneys, need to be working properly.
There are specific rules about who can't join. For example, you can't have had any other anti-cancer treatment in the four weeks before starting the study drugs. You also can't have certain other health problems, such as uncontrolled heart disease, ongoing serious lung inflammation, or active autoimmune diseases. If you have cancer that has spread to your brain, you might not be able to join unless it's been treated and is stable for at least a month. Your doctor will carefully check all these requirements to see if this study is right for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have advanced cancer that your doctor can measure?
- Are you generally well and able to perform daily activities?
- Have you had other anti-cancer treatments recently (within 4 weeks)? (If yes, you might not be eligible)
- Do you have any serious, uncontrolled heart problems or active autoimmune diseases?
- Is your doctor able to confirm that your organs are working well enough?
What does participation involve?
If you decide to take part in this study, you will have regular visits to the clinic for check-ups, scans, and blood tests to monitor your health and how the treatment is working. You'll receive the study drugs as prescribed by the research team. The exact number of visits, tests, and how long you'll receive treatment will depend on which group of the study you are in and how you respond to the treatment. There will also be a follow-up period after you finish the treatment to continue monitoring your health. The medical team will explain all these details clearly if you are considering joining.
Potential risks and benefits
Locations (42)
- University of California San DiegoVerified postcodeSan Diego, United States
- Hackensack University Medical CenterVerified postcodeBergen, United States
- GZA Ziekenhuizen campus Sint-AugustinusVerified postcodeAntwerp, Belgium
- Cliniques universitaires St Luc-UCLVerified postcodeBrussels, Belgium
- Jessa ZiekenhuisVerified postcodeHasselt, Belgium
- UZ LeuvenVerified postcodeLeuven, Belgium
- CHU HeloraVerified postcodeMons, Belgium
- Hôpital Saint AndréVerified postcodeBordeaux, France
- CHU CaenVerified postcodeCaen, France
- Centre Georges Francois LeclercVerified postcodeDijon, France
- Clinique Victor HugoVerified postcodeLe Mans, France
- Centre Oscar LambretVerified postcodeLille, France
Common questions
What is EOS-448?
EOS-448 is a new investigational drug being tested as a potential cancer treatment.
What does 'advanced solid tumours' mean?
It means cancers like lung, head and neck cancer, or melanoma that have spread or are difficult to treat with standard methods.
Will I still get my usual treatment?
The study is testing new combinations, sometimes with standard chemotherapy, but it will be different from your usual care.
Are there other names for EOS-448?
Yes, it's also known as GSK4428859A or belrestotug.
How long will the study last?
The duration varies depending on the specific part of the study and how you respond, but the team will discuss this fully with you.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.